Fundraising FoxMabGenesis
6 known investors
Find your way into MabGenesis
Sign up to see every warm intro you have to MabGenesis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MabGenesis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. Using its MOURA antibody library and IMPACT high-efficiency monoclonal antibody isolation technology, it targets high-unmet-need areas such as cancer and zoonotic diseases, and has built dog and cat antibody libraries for the veterinary drug market.
Investors · 6
Also in the syndicate · 3
Axil Capital PartnersMiyazaki Taiyo CapitalREVIC Capital
Frequently asked questions
- What does MabGenesis do?
- MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. Using its MOURA antibody library and IMPACT high-efficiency monoclonal antibody isolation technology, it targets high-unmet-need areas such as cancer and zoonotic diseases, and has built dog and cat antibody libraries for the veterinary drug market.
- Who are MabGenesis's investors?
- MabGenesis's investors include Beyond Next Ventures, Axil Capital, Long Black Partners.